SLC9A3 and hypertensive disorder: Taken together, these results are very promising, and we propose to further study and confirm this proof-of-concept hypothesis in different animal models of hypertension, especially in aTRH humans, by therapeutically targeting NHE3 in the proximal tubules of the kidney with or without other classes of antihypertensive drugs (Li et al., 2018, 2019b; Zhuo et al., 2021).